Author

Agnès Fernández-Clotet

SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB THERAPY IN CLINICAL PRACTICE: EFFICACY AND SAFETY IN INFLAMMATORY BOWEL DISEASE
SWITCH FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB THERAPY IN CLINICAL PRACTICE: EFFICACY AND SAFETY IN INFLAMMATORY BOWEL DISEASE

Agnès Fernández-Clotet  et al.

DISAGREEMENT BETWEEN ENDOSCOPIC AND TRANSMURAL HEALING IN CROHN’S DISEASE AND THE IMPACT OF DISEASE DURATION
DISAGREEMENT BETWEEN ENDOSCOPIC AND TRANSMURAL HEALING IN CROHN’S DISEASE AND THE IMPACT OF DISEASE DURATION

Agnès Fernández-Clotet  et al.

EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS AND OTHER INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OF GETECCU
EFFICACY OF BIOLOGICAL THERAPY FOR POUCHITIS AND OTHER INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THE QUESTION OF A SECOND ANTI-TNF AFTER ANTI-TNF FAILURE? RESULTS FROM THE RESERVO STUDY OF GETECCU

Agnès Fernández-Clotet  et al.

INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THERAPEUTIC REQUIREMENTS AFTER COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS. RESULTS FROM THE RESERVO STUDY OF GETECCU
INFLAMMATORY COMPLICATIONS OF THE POUCH, AND THERAPEUTIC REQUIREMENTS AFTER COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS. RESULTS FROM THE RESERVO STUDY OF GETECCU

Agnès Fernández-Clotet  et al.

INCIDENCE AND RISK FACTORS ASSOCIATED WITH RECURRENCE OF CROHN´S DISEASE AFTER DEFINITIVE PANPROCTOCOLECTOMY AND ILEOSTOMY: THE IFARPI STUDY
INCIDENCE AND RISK FACTORS ASSOCIATED WITH RECURRENCE OF CROHN´S DISEASE AFTER DEFINITIVE PANPROCTOCOLECTOMY AND ILEOSTOMY: THE IFARPI STUDY

Agnès Fernández-Clotet  et al.

REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY
REAL WORLD EVIDENCE OF USTEKINUMAB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS AND SAFETY: THE ULISES STUDY

Agnès Fernández-Clotet  et al.

IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY
IMPACT OF USTEKINUMAB ON EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES IN A COHORT OF PATIENTS WITH ULCERATIVE COLITIS IN REAL LIFE: THE ULISES STUDY

Agnès Fernández-Clotet  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Agnès Fernández-Clotet  et al.

REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES
REAL WORLD EVIDENCE OF TOFACINITIB IN ULCERATIVE COLITIS: SHORT AND LONG-TERM EFFECTIVENESS, SAFETY AND IMPACT OF EXTRAINTESTINAL MANIFESTATIONS AND IMMUNOMEDIATED DISEASES

Agnès Fernández-Clotet  et al.

ENDOSCOPIC STRICTUROTOMY VERSUS ENDOSCOPIC BALLOON DILATION FOR THE TREATMENT OF INTESTINAL STRICTURES IN CROHN'S DISEASE
ENDOSCOPIC STRICTUROTOMY VERSUS ENDOSCOPIC BALLOON DILATION FOR THE TREATMENT OF INTESTINAL STRICTURES IN CROHN'S DISEASE

Agnès Fernández-Clotet  et al.

LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU
LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU

Agnès Fernández-Clotet  et al.

SAFETY AND EFFICACY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN’S DISEASE AFTER CYCLOPHOSPHAMIDE-FREE MOBILIZATION: PRELIMINARY RESULTS
SAFETY AND EFFICACY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN’S DISEASE AFTER CYCLOPHOSPHAMIDE-FREE MOBILIZATION: PRELIMINARY RESULTS

Agnès Fernández-Clotet  et al.

THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU
THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU

Agnès Fernández-Clotet  et al.

IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU
IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU

Agnès Fernández-Clotet  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)

Agnès Fernández-Clotet  et al.

TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Agnès Fernández-Clotet  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)

Agnès Fernández-Clotet  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)
SAFETY OF INFLAMMATORY BOWEL DISEASE TREATMENTS IN PATIENTS WITH SOLID ORGAN TRANSPLANTATION (EITOS STUDY OF GETECCU)

Agnès Fernández-Clotet  et al.

Item 1 - 18 / 18
1